Sec Form 13G Filing - Champlain Investment Partners LLC filing for AVANOS MEDICAL INC. (AVNS) - 2022-02-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. ________)*

Avanos Medical, Inc.
(Name of Issuer)

COMMON STOCK
(Title of Class of Securities)

05350V106
(CUSIP Number)

12/31/2021
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:
/X/ Rule 13d-1(b)
    Rule 13d-1(c)
    Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a
reporting persons initial filing on this form with respect to
the subject class of securities, and for any subsequent
amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page
shall not be deemed to be filed for the purpose of Section 18
of the Securities Exchange Act of 1934 (Act) or otherwise
subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the
Notes).

Persons who respond to the collection of information contained
in this form are not
required to respond unless the form displays a currently valid
OMB control number.



13G
CUSIP No. 05350V106

1.  Names of Reporting Persons.
Champlain Investment Partners, LLC

2.  Check the Appropriate Box if a Member of a Group (See
Instructions)
(a) [ ]
(b) [ ]

3.  SEC Use Only

4.  Source of Funds (See Instructions)

5.  Check if Disclosure of Legal Proceedings Is Required
Pursuant to Items 2(d) or 2(e)
[ ]

6.  Citizenship or Place of Organization
Vermont

Number of Shares Beneficially Owned by Each Reporting
Person With:

7.  Sole Voting Power
994713

8.  Shared Voting Power


9.  Sole Dispositive Power
1174483

10.  Shared Dispositive Power

11.  Aggregate Amount Beneficially Owned by Each Reporting
Person
1174483

12.  Check if the Aggregate Amount in Row (11) Excludes Certain
Shares (See Instructions)
[ ]

13.  Percent of Class Represented by Amount in Row (11)
2.44%

14.  Type of Reporting Person (See Instructions)
IA



13G
CUSIP No.  05350V106


ITEM 1.
      (a) Name of Issuer:
		Avanos Medical, Inc.
      (b) Address of Issuer's Principal Executive Offices:
		5405 WINDWARD PARKWAY
                SUITE 100 SOUTH
		ALPHARETTA, GEORGIA 30004

ITEM 2.
      (a) Name of Person Filing:
		Champlain Investment Partners, LLC
      (b) Address of Principal Business Office, or if None,
Residence:
		180 Battery St., Burlington, Vermont 05401
      (c) Citizenship:
		Vermont
      (d) Title of Class of Securities:
		Common Stock
      (e) CUSIP Number:
		05350V106

ITEM 3.  IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b)
OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:


(a)
[_]
Broker or dealer registered under Section 15 of
the Act  (15 U.S.C. 78o).

(b)
[_]
Bank as defined in Section 3(a)(6) of the Act (15
U.S.C. 78c).

(c)
[_]
Insurance company as defined in Section 3(a)(19)
of the Act (15 U.S.C. 78c).

(d)
[_]
Investment company registered under Section 8 of
the Investment Company Act of 1940 (15 U.S.C. 80a-
8).

(e)
[x]
An investment adviser in accordance with
ss.240.13d-1(b)(1)(ii)(E);

(f)
[_]
An employee benefit plan or endowment fund in
accordance with ss.240.13d-1(b)(1)(ii)(F);

(g)
[_]
A parent holding company or control person in
accordance with ss.240.13d-1(b)(1)(ii)(G);

(h)
[_]
A savings associations as defined in Section 3(b)
of the Federal Deposit Insurance Act (12 U.S.C.
1813);

(i)
[_]
A church plan that is excluded from the definition
of an investment company under section 3(c)(14) of
the Investment Company Act of 1940 (15 U.S.C. 80a-
3);

(j)
[_]
Group, in accordance with ss.240.13d-
1(b)(1)(ii)(J).

ITEM 4. OWNERSHIP.

Provide the following information regarding the aggregate number
and percentage of the class of securities of the issuer
identified in Item 1.

      (a) Amount beneficially owned:
		1174483
      (b) Percent of class:
		2.44%
      (c) Number of shares as to which such person has:

      (i)  Sole power to vote or to direct the vote
		994713
      (ii) Shared power to vote or to direct the vote

      (iii) Sole power to dispose or to direct the disposition of
		1174483
      (iv) Shared power to dispose or to direct the disposition
of

INSTRUCTION. For computations regarding securities which
represent a right to acquire an underlying security SEE
ss.240.13d3(d)(1).




ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

If this statement is being filed to report the fact that as of
the date hereof the reporting person has ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following [X].

INSTRUCTION: Dissolution of a group requires a response to this
item.

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON.

If any other person is known to have the right to receive or the
power to direct the receipt of dividends from, or the proceeds
from the sale of, such securities, a statement to that effect
should be included in response to this item and, if such
interest relates to more than five percent of the class, such
person should be identified. A listing of the shareholders of an
investment company registered under the Investment Company Act
of 1940 or the beneficiaries of employee benefit plan, pension
fund or endowment fund is not required.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY
WHICH ACQUIRED THE     SECURITY BEING REPORTED ON BY THE PARENT
HOLDING COMPANY.

If a parent holding company or Control person has filed this
schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under
Item 3(g) and attach an exhibit stating the identity and the
Item 3 classification of the relevant subsidiary. If a parent
holding company or control person has filed this schedule
pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit
stating the identification of the relevant subsidiary.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE
GROUP.

If a group has filed this schedule pursuant to ss.240.13d-
1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an
exhibit stating the identity and Item 3 classification of each
member of the group. If a group has filed this schedule pursuant
to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating
the identity of each member of the group.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

Notice of dissolution of a group may be furnished as an exhibit
stating the date of the dissolution and that all further filings
with respect to transactions in the security reported on will be
filed, if required, by members of the group, in their individual
capacity. See Item 5.


ITEM 10. CERTIFICATIONS.

      (a) The following certification shall be included if the
statement is filed pursuant to Rule 13d-1(b):

"By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above
were acquired and are held in the ordinary course of
business and were not acquired and not held for the
purpose of or with the effect of changing or
influencing the control of the issuer of the securities
and were not acquired and are not held in connection
with or as a participant in any transaction having such
purpose or effect."

      (b) The following certification shall be included if the
statement is filed pursuant to Rule 13d-1(c):

"By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above
were not acquired and are not held for the purpose of
or with the effect of changing or influencing the
control of the issuer of the securities and were not
acquired and are not held in connection with or as a
participant in any transaction having such purpose or
effect."



SIGNATURE

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.


Date: 2/11/2022


Signature: Matthew Garcia


Name/Title: Matthew Garcia / Chief Compliance Officer



The original statement shall be signed by each person on whose
behalf the statement is filed or his authorized representative.
If the statement is signed on behalf of a person by his
authorized representative other than an executive officer or
general partner of the filing person, evidence of the
representative's authority to sign on behalf of such person
shall be filed with the statement, provided, however, that a
power of attorney for this purpose which is already on file with
the Commission may be incorporated by reference. The name and
any title of each person who signs the statement shall be typed
or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all
exhibits. See ss.240.13d-7 for other parties for whom copies are
to be sent.

Attention: Intentional misstatements or omissions of fact
constitute Federal criminal violations (See 18 U.S.C. 1001)